Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2014-12-31 Legal Proceedings Report
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2014年第九次临时股东大会法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, voting, and results of a specific shareholders' meeting (the 2014 ninth extraordinary general meeting) of a company. It details the legality and validity of the meeting and resolutions passed. It is not a financial report, earnings release, or management discussion. It is not a proxy solicitation or voting results announcement per se, but a legal opinion on the meeting's conduct and resolutions. Given the nature of the document as a legal opinion on a shareholders' meeting, it best fits under Legal Proceedings Report (LTR), which covers updates on legal matters involving the company, including legal opinions related to corporate governance and shareholder meetings.
2014-12-31 Chinese
2014年第九次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions from the 2014 ninth extraordinary general meeting of shareholders of the company. It details the meeting date, attendance, voting results on proposals, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2014-12-31 Chinese
华英证券有限责任公司关于细胞基因工程股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易资产过户情况之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" regarding a transaction involving issuance of shares and cash payment to purchase assets and raise supporting funds, including related party transactions. It references compliance with Chinese securities laws, approval by the China Securities Regulatory Commission, and detailed descriptions of the transaction structure, pricing, share issuance, lock-up periods, and asset transfer completion. The document is a detailed verification and advisory opinion by an independent financial advisor on a major asset restructuring transaction involving share issuance and cash payment. It is not a full annual or interim financial report, nor a simple announcement. It is a specialized advisory report related to a capital transaction and asset acquisition. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (over 12,000 characters) and detailed content confirm it is a substantive report, not just an announcement. Therefore, the classification is CAP with high confidence.
2014-12-29 Chinese
关于发行股份及支付现金购买资产并募集配套资金暨关联交易之标的资产过户完成情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of asset transfer related to a share issuance and cash payment for asset acquisition, along with fundraising activities. It includes details about the approval by the China Securities Regulatory Commission, the completion of equity transfer, and ongoing registration procedures. The document also contains opinions from independent financial and legal advisors confirming the compliance and completion of the transaction. The text is relatively short (1589 characters) and focuses on the announcement of the transaction completion and related procedural updates rather than providing detailed financial statements or comprehensive report content. Therefore, it fits best as a Capital/Financing Update (CAP) rather than a full Annual Report, Interim Report, or other detailed filings.
2014-12-29 Chinese
北京国枫凯文律师事务所关于中源协和细胞基因工程股份有限公司发行股份及支付现金购买资产之标的资产过户情况的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the completion of asset transfer in a major asset restructuring involving issuance of shares and cash payment. It references approvals from the China Securities Regulatory Commission and details about the asset transfer registration. The document is a standalone legal opinion related to a capital transaction and asset acquisition, not a full financial report, earnings release, or management discussion. It is not a regulatory announcement or a report publication notice but a legal audit-type document providing assurance on the transaction's legal status. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting or legal opinions related to transactions. FY 2014
2014-12-29 Chinese
上海执诚生物科技股份有限公司财务报表及审计报告（2014年度1-6，2013年度和2012年度）
Regulatory Filings
2014-12-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.